HK Stock Market Move | MEDBOT-B(02252) rises more than 11%, the commercialization effect of Siasun Robot&Automation's surgery is evident, and institutions are optimistic that it will reach a turning point in profitability.

MEDBOT-B(02252) rose more than 11%, as of the time of writing, it rose by 11.72% to 23.35 Hong Kong dollars, with a turnover of 2.8 billion Hong Kong dollars. On the news front, Siasun Robot & Automation recently announced that its independently developed Tuomai single-arm single-hole endoscope surgery Siasun Robot & Automation (Tuomai single-arm) has obtained registration approval from the National Medical Products Administration (NMPA), indicating that its overall performance, innovation level, and clinical effectiveness and safety have been certified by the national regulatory authorities. In addition, the comprehensive order volume of Siasun Robot & Automation's core products in laparoscopy, orthopedics, and vascular intervention under the MicroPort umbrella has exceeded 100 units. During this period, the global order volume for Tuomai endoscopic surgery Siasun Robot & Automation reached 39 units, with a breakthrough of more than 30 units in commercial installations, and a total of nearly 60 units in global commercial orders. Southwest recently released a research report stating that the company's "three-quarters" of the Siasun Robot & Automation version has been completed, and 2025-2026 will be an important turning point for profit; in addition, the relaxation of domestic equipment allocation policies has expanded the market, with a 215% increase in planned numbers for laparoscopic surgery Siasun Robot & Automation in the new version of medical equipment allocation certificates in June 2023. The company's order volume has doubled for two consecutive years; the overseas market has rapidly broken through, with more than 20 overseas orders approved in the first year of commercialization, and the 5G remote surgery solution has helped promote academic promotion and installation in hospitals.